Stryker (NYSE:SYK) Change In Receivables

: $-112 Mil (TTM As of Jun. 2023)

View and export this data going back to 1988. Start your Free Trial

Stryker's change in receivables for the quarter that ended in Jun. 2023 was $-57 Mil. It means Stryker's Accounts Receivable increased by $57 Mil from Mar. 2023 to Jun. 2023 .

Stryker's change in receivables for the fiscal year that ended in Dec. 2022 was $-579 Mil. It means Stryker's Accounts Receivable increased by $579 Mil from Dec. 2021 to Dec. 2022 .

Stryker's Accounts Receivable for the quarter that ended in Jun. 2023 was $3,261 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Stryker's Days Sales Outstanding for the three months ended in Jun. 2023 was 59.56.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Stryker's liquidation value for the three months ended in Jun. 2023 was $-13,828 Mil.

Stryker Change In Receivables Historical Data

The historical data trend for Stryker's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

-60.00

-563.00

354.00

-377.00

-579.00

Stryker Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Receivables																-212.00	-27.00	-393.00	365.00	-57.00

Stryker Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112 Mil.

Stryker (NYSE:SYK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Stryker's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3261	/	4996	*	91
=	59.56

2. In Ben Graham's calculation of liquidation value, Stryker's accounts receivable are only considered to be worth 75% of book value:

Stryker's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1478	-	20048	+	0.75 * 3261	+	0.5 * 4593
=	-13,828

Stryker Change In Receivables Related Terms

Thank you for viewing the detailed overview of Stryker's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Stryker (NYSE:SYK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stryker Corp (NYSE:SYK) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SYK:Mexico SYK:Germany S1YK34:Brazil SYK:Austria

Address

2825 Airview Boulevard, Kalamazoo, MI, USA, 49002

Website

https://www.stryker.com

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Executives

James Andrew Pierce	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Spencer S Stiles	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Skeete Tatum Lisa M	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher	officer: VP, Chief Legal Officer	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Viju Menon	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Sherilyn S Mccoy	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Rajeev Suri	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary K Brainerd	director	8170 33RD AVENUE SOUTH, BLOOMINGTON MN 55425
Graham A Mclean	officer: President, Asia-Pacific	1 CORPORATE AVENUE ROWVILLE, VICTORIA C3 3178
Glenn S Boehnlein	officer: Vice President, CFO	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink	officer: VP, Global Human Resources	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Yin C Becker	officer: VP, Comm. & Public Affairs	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Bijoy Sagar	officer: VP, Chief Information Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Michael Damon Hutchinson	officer: General Counsel	2825 AIRVIEW BLVD, KALAMAZOO MI 49002